Form 8K Corcept Therapeutics Incorporated For: 31 December
Setback for Corcept: FDA Issues Complete Response Letter for Relacorilant in Hypercortisolism Treatment Corcept Therapeutics Incorporated (NASDAQ: CORT) disclosed in a Form 8-K filing on December 31, 2025, that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant as a treatment for patients … Read more